Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients-Reference-Cited by-同舟云学术

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Published:2020-09-17 Issue:11 Volume:72 Page:2021-2024
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Falcone Marco¹,Tiseo Giusy¹,Nicastro Manuela²,Leonildi Alessandro³,Vecchione Alessandra³,Casella Costanza²,Forfori Francesco²⁴,Malacarne Paolo²,Guarracino Fabio²,Barnini Simona³,Menichetti Francesco¹

Affiliation:

1. Infectious Diseases Azienda Ospedaliera Universitaria Pisana Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

2. Department of Anaesthesia and Critical Care Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

3. Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

4. Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy

Abstract

Abstract Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase–producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1410/34053789/ciaa1410.pdf

Reference11 articles.

1. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae;Falcone;Crit Care,2020

2. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales;Falcone;Clin Infect Dis,2020

3. Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa;Cai;Open Forum Infect Dis,2017

4. Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature;Zingg;Open Forum Infect Dis,2020

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria;Antibiotics;2024-09-12

2. Crystal Structures of the Acinetobacter baumannii Macrolide Phosphotransferase E;ACS Infectious Diseases;2024-09-10

3. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections;JAC-Antimicrobial Resistance;2024-09-03

4. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy;Antimicrobial Resistance & Infection Control;2024-08-26

5. Effective strategies for managing trimethoprim-sulfamethoxazole and levofloxacin-resistant Stenotrophomonas maltophilia infections: bridging the gap between scientific evidence and clinical practice;Current Opinion in Infectious Diseases;2024-07-30